Jagsonpal Pharmaceuticals (JAGSNPHARM) Q1 26/27 earnings summary

Executive summary

• Achieved 9% year-over-year revenue growth in Q1 FY27, with operating EBITDA up 21% and PAT up 22%, outpacing industry growth rates.

• Completed acquisition of 85% stake in Aequitas Healthcare, entering the hospital segment and expanding specialty access.

• Executed a successful ₹400 million share buyback, subscribed 3.67x at a 40% premium, improving ROCE by 340 bps.

• Board changes included the addition of an experienced independent director.

• Unaudited financial results for the quarter ended 30 June 2026 were reviewed and approved by the Board and statutory auditors.

Financial highlights

• Revenue from operations rose to ₹822.32 million, gross profit to ₹540 million, and gross margin improved to 65.2%.

• Operating EBITDA reached ₹191 million (margin at 23.2%), expanding by 240 bps.

• PAT increased to ₹132 million, with margin improvement to 16.0%.

• ROCE and ROE improved by 340 bps and 250 bps, respectively.

• Maintained a healthy closing cash balance of ₹1,700 million.

Outlook and guidance

• Targeting revenue growth at 1.5x the Indian pharma industry rate, with Aequitas expected to reach ₹1,000 million revenue and ₹100 million EBITDA within 2.5 years.

• Focus remains on organic growth, successful integration of Aequitas, and disciplined capital allocation.

• The company is evaluating the impact of newly notified Code of Wages (Central) Rules, 2026, and will update accounting as needed.